Condition: Major Depressive Disorder · Sponsor: Neurocrine Biosciences
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
This description comes directly from the study's public registry record.
Neurocrine Medical Information Call Center · 1-877-641-3461 · medinfo@neurocrine.com
Always discuss trial participation with your own doctor first.
| Neurocrine Clinical Site | Chino, California, United States | Recruiting |
| Neurocrine Clinical Site | Los Angeles, California, United States | Recruiting |
| Neurocrine Clinical Site | Stanford, California, United States | Recruiting |
| Neurocrine Clinical Site | Aurora, Colorado, United States | Recruiting |
| Neurocrine Clinical Site | Cromwell, Connecticut, United States | Active Not Recruiting |
| Neurocrine Clinical Site | Farmington, Connecticut, United States | Active Not Recruiting |
| Neurocrine Clinical Site | Maitland, Florida, United States | Recruiting |
| Neurocrine Clinical Site | Miami, Florida, United States | Recruiting |
| Neurocrine Clinical Site | Tampa, Florida, United States | Withdrawn |
| Neurocrine Clinical Site | Gaithersburg, Maryland, United States | Active Not Recruiting |
| Neurocrine Clinical Site | Cedarhurst, New York, United States | Recruiting |
| Neurocrine Clinical Site | New York, New York, United States | Active Not Recruiting |
+ 22 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.